Menu
Recruiting NCT03770702

Statins and ARBs on Rheumatoid Activity

Phase III Interventional Rheumatoid Arthritis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Angiotensin receptor blockers, Statins.
Who it may be relevant to
Registry conditions: Rheumatoid Arthritis. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Investigational and Comparative Study Between the Anti-inflammatory Effectof Both Angiotensin Reeptor Blockers and Statins on Rheumatoid Arthritis Disease Activity on Egyptian Patients

Overview

Investigational and comparative study between the anti-inflammatory effectof both angiotensin reeptor blockers and statins on rheumatoid arthritis disease activity on Egyptian patients

Detailed description

The study aims at ivestigating and comparing the anti-inflammatory effectof both angiotensin reeptor blockers and statins on rheumatoid arthritis disease activity on Egyptian patients

Interventions

  • Drug Angiotensin receptor blockers
    Candesartan
  • Drug Statins
    Atorvastatin

Primary outcome measures

  • Change in disease activity score [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • Rheumatoid arthritis.

Exclusion criteria

  • Pregnant or lactating
  • Hepatic or renal impairment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Sherief Abd-Elsalam — Tanta

Identifiers

NCT: NCT03770702 · Rheumatoid

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗